Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. - Wikidata - wikimedia - TriplyDB

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q46329140

about

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy Vascular Complications of Cancer Chemotherapy What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer Therapy Cardiac toxicity in cancer survivors Cardiac effects of anticancer therapy in the elderly The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.Cardiomyocyte autophagy and cancer chemotherapy.Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention Sorafenib cardiotoxicity increases mortality after myocardial infarction.Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.Cardiotoxicity of the anticancer therapeutic agent bortezomib.Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.New trial designs and potential therapies for pulmonary artery hypertension.Cardiovascular disease in adult survivors of childhood cancer.Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors.Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats.Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.An update on cardio-oncology.

P2860

Q21261282-3B925E60-1AB0-4A07-A54F-EED4AF38CC83 Q22305863-0E72C258-1005-4425-89F7-CC6DE7099CEB Q26743433-6053E98C-86EE-4294-AB2B-6CACE56A5BA6 Q26766269-5AFF3FED-29CC-4D08-B67D-5D3F6E7CD203 Q26782585-FF82C5C1-5982-4E5B-A432-95AFB3B24F4B Q26797138-CA49DB1D-27E1-41AE-8461-1223E9BA48FF Q26851957-F837F6DE-AEAF-4703-9EFD-934B8E168C21 Q26863244-AC246C18-60DB-4347-8A9F-1AA5B58BF528 Q27011540-9122CC0A-EB6D-438C-819F-23EEF74FC630 Q27013665-0B4A2CC9-EE3D-41F5-80E2-487FD976F94D Q27027354-B72C26A4-B88B-46FE-B7AF-D993616D3F95 Q28087776-8C077E61-2CFE-45E4-99D6-ECC4CE63979C Q28545130-84BD89B6-4F9F-45C8-8D1C-FB44F51E80B5 Q28550236-88187413-BAB6-4F6D-8CD3-75A281D1129D Q30240748-115284CA-8BD3-4AA1-B844-DA055A960E56 Q30399577-85121AF4-FC43-4123-86D2-A0B820819549 Q30401812-4BBBAD26-1D2B-483E-9411-18A25E4FB31D Q30426853-E1D69759-1223-4AFD-B6FD-248D3593F048 Q30492863-B7CDBA74-8780-4E62-93DC-7771D2BF90FE Q30847302-DB89FCAD-A2AE-421C-8BC6-DACA0507EB31 Q33395853-ADF1EE69-4330-44CB-B845-2678783FACBE Q33573823-B2E746A7-D84A-47BE-AECA-17EEBBAB5A3E Q33574045-247AD3BA-983B-4878-B676-A004195A47EA Q33681995-964A9518-BBF9-4BCD-8270-5BDE0959E7D0 Q33692402-E7F31957-3060-4C51-864B-0A49FB9EB364 Q33698419-E8BDF93F-72E3-4DC1-AB05-C3A3E2232956 Q33807542-73D5187B-E508-40CA-8009-3CD50EE78B05 Q33828690-3CF43F05-4FC8-436A-B704-AEBCBBE982F9 Q33882390-97310AC1-E6B7-43DB-9082-FDAAEB662526 Q33916002-4BD4AF41-5DFE-4D6B-8490-12B571651C75 Q33982467-012258AD-B0E9-464D-B081-A1F15C5E102B Q34042984-E9622E92-84CC-48D9-B91A-726F67831E32 Q34111200-A96696EE-1041-456F-8A46-0E65350A87D9 Q34289211-1C427A34-73ED-41B5-8017-0202B496EB39 Q34292469-30B82BE4-8192-4F47-9803-2C4CD2B76178 Q34352627-88E7E7F6-93EF-4841-93AE-150BB3A4872C Q34441749-8A02E55D-8D08-4B60-9720-E6EC5D1A6971 Q34443523-5C8A5EB2-32DB-4B6C-8327-0E5972A4306B Q34488671-E1790578-43AC-48E8-8A63-25409FE95164 Q34650059-41F505F9-68E4-4181-9A1A-B5557C8BAEFF

P2860

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q46329140

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.

@en

Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.

@nl

type

label

Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.

@en

Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.

@nl

prefLabel

Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.

@en

Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.

@nl

P1433

Q46329140-CF432F60-8565-4E4C-9B55-459DAABD77B5

P1476

Q46329140-4C4C72C5-C496-4346-BF40-2C09BAB6A82D

P2093

Q46329140-1C66C7AE-28EC-421E-8393-322923C51086

Q46329140-3D392A65-C66F-4FDE-90BC-4941BFF920F8

Q46329140-5344BD4B-4D00-441A-93AC-F59EFD6B01D9

Q46329140-5E9F670B-7906-4DFC-988F-21F9A8D1C3F9

Q46329140-704D3CEE-E59F-4C42-835E-7C597050F9AD

Q46329140-988C2726-D73C-487D-937B-4508EA253C0D

Q46329140-9956FE9A-8636-44DF-8F68-0356C37AAFC2

Q46329140-DAA2D107-B9D4-4D53-A4C7-D09145E93BE5

Q46329140-E9A5A931-158B-4F31-A5A2-D442A21BB606

P304

Q46329140-BB0BFD8F-A79D-40B6-8CC9-9E58224DB95E

P31

Q46329140-AC240EAB-349D-4B5D-BC44-BCD2D728C313

P356

Q46329140-26A771E7-0FE1-46BF-B3EE-6A9FA0F6AAD1

P407

Q46329140-E2109800-3CFD-433D-9E07-2AB7FACC95DF

P433

Q46329140-51E41663-0515-43A1-93F5-C603B953625B

P478

Q46329140-C9B4DF59-2C3C-4B2E-9A20-649085A686F6

P577

Q46329140-F33C159E-37F4-4E76-AAD1-394A2DED5B5C

P698

Q46329140-C30D7E97-2250-4F2E-BE1C-B0AE7969D931

P921

Q46329140-A5CA00A2-5220-42FE-9BDB-A703C5383AFC

P356

JCO.2007.15.6331

P1433

Journal of Clinical Oncology

P1476

Cardiac toxicity of sunitinib ...... tastatic renal cell carcinoma.

@en

P2093

Andja Bojic

http://www.w3.org/2001/XMLSchema#string

Christoph C Zielinski

http://www.w3.org/2001/XMLSchema#string

Christoph Schukro

http://www.w3.org/2001/XMLSchema#string

Herwig Schmidinger

http://www.w3.org/2001/XMLSchema#string

Manuela Schmidinger

http://www.w3.org/2001/XMLSchema#string

Marija Bojic

http://www.w3.org/2001/XMLSchema#string

Marquerite Ruhsam

http://www.w3.org/2001/XMLSchema#string

Michael Hejna

http://www.w3.org/2001/XMLSchema#string

Ursula M Vogl

http://www.w3.org/2001/XMLSchema#string

P304

5204-5212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.15.6331

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18838713

http://www.w3.org/2001/XMLSchema#string

P921